Antibe Therapeutics Inc(Pre-Merger) T.ATE

Alternate Symbol(s): ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

TSX:ATE - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Comment by Bobwinson Apr 21, 2018 11:02pm

168 Views

Post# 27922659

RE:RE:RE:WOW ATE TARGET 1.40 !!!!

The analyst gave a 1 year price target of C$1.40 so it's not that unreasonable. In the analysis there are pluses and minuses. He used a royalty rate of up to 30% so income is much higher after commercialization BUT he uses 2024 as the approval and commercialization date. This is far later than Zack's date of 2021. In order for Antibe to get that high a royalty rate, they would probably have to finance the phase III trials themselves. Given the company's preference for finding a phase III partner to finance the trials, this seems odd.

Bullboard Posts

Aston Bay unearths thick new copper zones in Nunavut